Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-36004
Proc Natl Acad Sci U S A. May 8, 2007; 104 (19): 8059-64.

Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Ng HJ , Whittemore ER , Tran MB , Hogenkamp DJ , Broide RS , Johnstone TB , Zheng L , Stevens KE , Gee KW .


Abstract
Activation of brain alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) has broad therapeutic potential in CNS diseases related to cognitive dysfunction, including Alzheimer''s disease and schizophrenia. In contrast to direct agonist activation, positive allosteric modulation of alpha7 nAChRs would deliver the clinically validated benefits of allosterism to these indications. We have generated a selective alpha7 nAChR-positive allosteric modulator (PAM) from a library of GABAA receptor PAMs. Compound 6 (N-(4-chlorophenyl)-alpha-[[(4-chloro-phenyl)amino]methylene]-3-methyl-5-isoxazoleacet-amide) evokes robust positive modulation of agonist-induced currents at alpha7 nAChRs, while preserving the rapid native characteristics of desensitization, and has little to no efficacy at other ligand-gated ion channels. In rodent models, it corrects sensory-gating deficits and improves working memory, effects consistent with cognitive enhancement. Compound 6 represents a chemotype for allosteric activation of alpha7 nAChRs, with therapeutic potential in CNS diseases with cognitive dysfunction.

PubMed ID: 17470817
PMC ID: PMC1876571
Article link: Proc Natl Acad Sci U S A.

Genes referenced: pam
Antibodies referenced:

My Xenbase: [ Log-in / Register ]
version: [3.2.1]


Major funding for Xenbase is provided by the National Institute of Child Health and Human Development, grant P41 HD064556